712MO Final overall survival (OS) from the phase III ATALANTE/ENGOT-ov29 trial evaluating atezolizumab (Atz) versus placebo with standard chemotherapy (Cx) plus bevacizumab (bev) in ovarian cancer (OC) patients (pts) with platinum-sensitive relapse (PSR).

Authors :: Kurtz, J.E.
Pujade-Lauraine, E.
Oaknin, A.
Belin, L.
Grimm, C.
Kocian, R.
Denys, H.
Rosengarten, O.S.
Follana, P.
Sehouli, J.
Martinez-Garcia, J.
Alexandre, J.
Hardy-Bessard, A-C.
Frenel, J-S.
Sabatier, R.
Gladieff, L.
De La Motte Rouge, T.
Lamichhane, N. Bonichon
Kalbacher, E.
Heitz, F.
Source :: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS546-S546. 1p.
Publication Year :: 2024

Subjects :: *CLINICAL trials
*OVERALL survival
*OVARIAN cancer
*ATEZOLIZUMAB
*BEVACIZUMAB

Full Text Access

Tools